Pancreatic Cancer Research

ResearcherParacelsus Medical UniversityActive in the last 2 years

Richard Greil

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-4462-3694; OpenAlex author ID A5039994927. Sources: OpenAlex.

Their work

Papers
16 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
31
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 2 papers · 2019: 2 papers · 2020: 2 papers · 2021: 5 papers · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper

Papers 16

  1. Chemotherapy sequence in advanced pancreatic cancer – still a matter of debate? Co-author DOI 10.21203/rs.3.rs-4461811/v1↗
  2. Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-c… Co-author DOI 10.1002/cam4.6334↗
  3. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  4. Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel. Co-author DOI 10.1055/a-1548-4847↗
  5. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis. Co-author DOI 10.1016/j.ejca.2021.03.040↗
  6. Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2021.09.004↗
  7. Non-pegylated Liposomal Doxorubicin as Palliative Chemotherapy in pre-Treated Advanced Pancreatic Cancer: A Retrospective Analysis of Twenty-Eight Patients. Last author DOI 10.1177/15330338211042139↗
  8. Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gem… Co-author DOI 10.1200/jco.20.02232↗
  9. Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy-A Review of the Literature. Last author DOI 10.3390/biom11101469↗
  10. The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc anal… Co-author DOI 10.1177/1758835919900872↗
  11. Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients. Co-author DOI 10.2144/fsoa-2020-0128↗
  12. Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine. Co-author DOI 10.1177/1756284819877635↗
  13. C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling overall survival Prediction in Pancreatic Cancer Patients. Co-author DOI 10.3390/jcm8111791↗
  14. Nonmetastatic pancreatic cancer : Improved survival with chemoradiotherapy > 40 Gy after systemic treatment. Co-author DOI 10.1007/s00066-018-1281-7↗
  15. Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters. Co-author DOI 10.1371/journal.pone.0206688↗
  16. Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review. Last author DOI 10.3892/ijo.2013.2176↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Konstantin Schlick · 10 shared papers, 2018–2024 · strength 1.42
  2. Lukas Weiß · 6 shared papers, 2018–2024 · strength 0.88
  3. Armin Gerger · 4 shared papers, 2020–2024 · strength 0.52
  4. Jakob Michael Riedl · 4 shared papers, 2020–2024 · strength 0.52
  5. Martin Pichler · 3 shared papers, 2019–2022 · strength 0.32
  6. Alexander Egle · 3 shared papers, 2018–2021 · strength 0.29
  7. Daniel Neureiter · 2 shared papers, 2021 · strength 0.27
  8. Michael Stotz · 2 shared papers, 2021–2022 · strength 0.23
  9. Florian Moik · 2 shared papers, 2021–2022 · strength 0.23
  10. Dominik Andreas Barth · 2 shared papers, 2021–2022 · strength 0.23
  11. Gabriel Rinnerthaler · 3 shared papers, 2014–2020 · strength 0.21
  12. Wolfgang Eisterer · 2 shared papers, 2019–2020 · strength 0.18
  13. Gerald W. Prager · 2 shared papers, 2019–2020 · strength 0.18
  14. Florian Hohla · 2 shared papers, 2014–2020 · strength 0.14
  15. Stefan Stättner · 2 shared papers, 2014–2020 · strength 0.14
  16. Cihan Ay · 1 shared paper, 2022 · strength 0.12
  17. Ivelina Gueorguieva · 1 shared paper, 2021 · strength 0.11
  18. Andrés Jesús Muñoz Martín · 1 shared paper, 2021 · strength 0.11
  19. Sara Lonardi · 1 shared paper, 2021 · strength 0.11
  20. Joel Randolph Hecht · 1 shared paper, 2021 · strength 0.11
  21. Baek‐Yeol Ryoo · 1 shared paper, 2021 · strength 0.11
  22. Joon Oh Park · 1 shared paper, 2021 · strength 0.11
  23. Johanna C. Bendell · 1 shared paper, 2021 · strength 0.11
  24. Charles D. Lopez · 1 shared paper, 2021 · strength 0.11
  25. Eric Van Cutsem · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.